MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

InVisionFirst (Inivata) plasma-based somatic CGP is covered for patients with advanced (Stage IIIB/IV) NSCLC when tissue-based CGP is infeasible (QNS or biopsy contraindicated) and either at diagnosis when specific tumor marker results (EGFR, ALK, ROS1, BRAF) are unavailable, at progression post-chemotherapy/immunotherapy for patients not previously tested for these markers, or when progressing on EGFR TKIs. If ctDNA is insufficient or no alteration is detected, tissue-based genotyping should be considered. Coverage for other stages or histologies and scenarios where tissue CGP is feasible is not specified and requires case-by-case review.

"InVisionFirst (plasma-based somatic CGP) is covered for patients with advanced (Stage IIIB/IV) non-small cell lung cancer (NSCLC) at diagnosis when results for EGFR SNVs/indels, ALK and ROS1 rearra..."

Sign up to see full coverage criteria, indications, and limitations.